Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma-Reference-Cited by-同舟云学术

Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma

Published:2023-12 Issue: Volume:261 Page:115833
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Liu Linfu,Zhang Liyuan,Chen Xuxi,Yang Kang,Cui Hao,Qian Rui,Zhao Shanshan,Wang Liqun,Su Xiaolan,Zhao Manyu,Wang Mengzhu,Hu Zan,Lu Tao,Zhu Yong,Zhou Qing-Qing^ORCID,Yao Yuqin

Funder

National Natural Science Foundation of China

China Pharmaceutical University

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference30 articles.

1. Diagnosis and management of multiple myeloma: a review;Cowan;JAMA,2022

2. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management;Rajkumar;Am. J. Hematol.,2022

3. Extramedullary disease in multiple myeloma: a systematic literature review;Bladé;Blood Cancer J.,2022

4. Targeting histone deacetylases in malignant melanoma: a future therapeutic agent or just great expectations?;Garmpis;Anticancer Res.,2017

5. Histone deacetylase inhibitors in cancer therapy;Sun;Curr. Top. Med. Chem.,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HDAC6 mediates tumorigenesis during mitosis and the development of targeted deactivating agents;Bioorganic Chemistry;2024-09

2. Benzimidazole‐Containing Compounds as Anticancer Agents;ChemistrySelect;2024-08-22

3. Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment;BMC Medical Genomics;2023-11-17